TRAVERE THERAPEUTICS INC
NASDAQ: TVTX (Travere Therapeutics, Inc.)
Last update: 9 hours ago50.08
-2.35 (-4.48%)
| Previous Close | 52.43 |
| Open | 52.00 |
| Volume | 2,314,346 |
| Avg. Volume (3M) | 1,685,706 |
| Market Cap | 4,720,594,944 |
| Price / Earnings (Forward) | 42.37 |
| Price / Sales | 9.79 |
| Price / Book | 244.01 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2026 |
| Profit Margin | -82.88% |
| Operating Margin (TTM) | -52.21% |
| Diluted EPS (TTM) | -2.78 |
| Quarterly Revenue Growth (YOY) | 97.50% |
| Total Debt/Equity (MRQ) | 1,220.07% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | -160.66 M |
| Levered Free Cash Flow (TTM) | -239.23 M |
| Return on Assets (TTM) | -23.21% |
| Return on Equity (TTM) | -422.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Travere Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.00 |
Select this tab to load the latest available analysis.
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 113.30% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DUBE ERIC M | - | 52.79 | -243,735 | -12,866,771 |
| Aggregate Net Quantity | -243,735 | |||
| Aggregate Net Value ($) | -12,866,771 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 52.79 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DUBE ERIC M | Officer | 15 Oct 2026 | Automatic sell (-) | 243,735 | 52.79 | 12,866,771 |
| DUBE ERIC M | Officer | 15 Oct 2026 | Option execute | 243,735 | - | - |
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |